Zenagamtide is the official name, given in 2026, for amycretin, Novo Nordisk's investigational drug that activates both the GLP-1 and amylin receptors in a single molecule. Novo is testing it as a weekly injection and as a pill.
At the ADA meeting in June 2026, Novo reported a Phase 2 trial in 262 adults with type 2 diabetes: at the top 40 mg dose, HbA1c fell 1.71 percentage points and body weight 14.6% at 36 weeks. Phase 3 trials in the AMAZE program, including AMAZE-12 on keeping weight off, are under way.
The drug is not approved anywhere, yet a JAMA news report in October 2026 found it sold online alongside Lilly's retatrutide, often labeled for research use only.
See #amycretin, #amylin, and #novo-nordisk.
A JAMA Medical News report published October 9, 2026 found dozens of websites, promoted by TikTok and Instagram influencers, selling Eli Lilly's investigational triple agonist retatrutide and Novo Nordisk's GLP-1 and amylin drug zenagamtide, often labeled "for research purposes only" while giving dosing instructions. Neither drug is approved anywhere. Australia's drug regulator found a product labeled retatrutide that contained a high dose of semaglutide instead, and University of Queensland tests of three 10 mg vials found doses from about half to about twice the label; the FDA has sent 21 warning letters to retatrutide sellers since December 2024, according to the report.
Novo Nordisk presented Phase 2 data for zenagamtide (formerly amycretin), its unimolecular GLP-1 and amylin receptor agonist, at ADA 2026 in 262 adults with type 2 diabetes randomized across six subcutaneous doses (0.4 to 40 mg) versus placebo. The 40 mg arm cut HbA1c by 1.71 percentage points and reduced body weight by 14.6% at 36 weeks, with nearly 89% of patients reaching HbA1c below 7%. The study met its primary HbA1c endpoint across all doses; Novo plans Phase 3 in H2 2026 and hosted a same-day R&D investor event.
Novo Nordisk hosted its R&D investor event in New Orleans on Sunday June 7, the same day as the CagriSema and zenagamtide readouts. The pipeline conversation centered on the combination strategy that pairs CagriSema and zenagamtide with the Wegovy injection and Wegovy pill, plus IcoSema and the FGF21 analog efruxifermin in MASH. Across 40 ADA abstracts, the company is reframing itself from a single-product GLP-1 leader to a multi-mechanism cardiometabolic pipeline.
Ahead of the ADA Scientific Sessions (June 5-8, New Orleans), Novo Nordisk previewed 40 abstracts spanning pivotal Phase 3 CagriSema in the REIMAGINE type 2 diabetes program, new mid-stage data for the amylin/GLP-1 agonist zenagamtide (the molecule previously called amycretin), and IcoSema and semaglutide analyses. Novo said its obesity and diabetes products reached 45.3 million patients by March 2026, with obesity up 58% year over year, and will host an R&D investor event June 7.